Impact of a High-resolution Program for the Prevention of Suicidal Behavior in At-risk Adults: a Quasi-experimental Ambispective Cohort Study

Background: Suicidal behavior represents a major public health problem worldwide. According to the World Health Organization (WHO), approximately 720.000 people die by suicide annually, and many more attempt it. Suicide is a personal tragedy associated with extreme suffering that has a serious impact on the deceased's immediate circle and on society as a whole. In this context, there is an urgent need to design effective and humane intervention strategies that offer an evidence-based, preventive, specialized, and community-oriented response to suicidal behavior.

Objective: To evaluate the impact of a multidisciplinary, specialized, and high-resolution program for the prevention of suicidal behavior in adults aged 18 and over in the Salamanca Health Area.

Methods: A quasi-experimental, ambispective cohort study with two parallel groups: an intervention group, receiving the specific suicide prevention program (SPP) with a pre-test/post-test design, and a control group, receiving usual care (TC). Adult patients (≥ 18 years) will be referred from the Emergency Department of the University Hospital of Salamanca after an initial psychiatric evaluation. Patients will be assigned to the intervention group according to established inclusion criteria. The program lasts 3 months, during which each participant will receive intensive and individualized follow-up from a multidisciplinary team composed of two psychiatrists, two mental health nurses, two psychologists, and two social workers at two community mental health centers. Participants will also attend 10 weekly group therapy sessions. Follow-up evaluations will be conducted at the end of the program (three months) and six months after the first contact.

Discussion: This study will contribute to the scientific evidence base on the effectiveness of intensive and specific suicide prevention programs in the community setting, optimizing healthcare resources, improving treatment adherence, and aligning with the Spanish National Suicide Prevention Plan 2025-2027. Ethics and dissemination: This study has been approved by the Clinical Research Ethics Committee of the Salamanca Health Area (CEIm code: PI 2025 11 2102 - TD)

Keywords: Suicidal behavior; Suicide prevention; Suicidal ideation; Community mental health services; Quasi-experimental study; Cohort study; Psychiatric emergency services; Patient care team.

Study Overview

• Status: Recruiting
• Conditions: Prevention of Suicidal Behavior
• Intervention / Treatment: Behavioral: PPS; SUICIDE PREVENTION PROGRAM

Detailed Description

INTRODUCTION.

Epidemiological and Clinical Impact of Suicidal Behavior. Suicidal behavior is a phenomenon of increasing impact and one of the main public health concerns globally. According to the most recent data from the World Health Organization (WHO), published in 2025, more than 720,000 people die by suicide each year worldwide, a figure far exceeded by the number of attempts. It is estimated that for every completed suicide, there are approximately 20 attempts, and this is why these prior suicidal behaviors are consolidated as the individual risk factor with the greatest predictive value for future episodes. Suicidal behaviors generate extreme suffering with profound repercussions for both the individual and their socio-familial environment, thus generating a health and social impact of great magnitude. This is why suicide prevention has currently become a strategic priority on public health agendas.

In Spain, according to the latest data from the National Institute of Statistics (INE), there were 4,116 deaths by suicide in 2023, making it the second leading cause of death from external causes. The crude rate is 8.5 suicides per 100,000 inhabitants, with a notably asymmetrical distribution between sexes: 74% of cases correspond to men and 26% to women. These figures translate to an average of ten people committing suicide in Spain every day, highlighting the urgent need for effective clinical and preventative interventions.

Regulatory and strategic framework. The prevention of suicidal behavior is based on a solidly defined international and national strategic framework. Globally, the WHO's Action Plan for Suicide Prevention 2013-2030 establishes, in its third objective, the imperative need to implement mental health promotion and prevention strategies throughout the life cycle, with a commitment to reducing the suicide rate by one-third by 2030. In the Spanish context, the National Health System's (SNS) Mental Health Strategy 2022-2026 prioritizes, in its third strategic line, strengthening prevention, early detection, and optimizing the quality of care in this area. These guidelines are reinforced by the SNS's specific Action Plan for Suicide Prevention 2025-2027, which intensifies these measures with special emphasis on the most vulnerable groups and promotes intersectoral coordination as a response from the healthcare system.

Under this paradigm, the need arises to design effective and humanized intervention strategies as a comprehensive response, offering an effective response to the problem of suicide from a preventive, specialized, and community-based approach. Suicidal behavior is a preventable phenomenon through systematic and multidisciplinary actions.

Preventive interventions in suicidal behavior. Given the increase in deaths by suicide, there has been a proliferation of research focused on the development and evaluation of preventive strategies. In this area, it has become clear that preventive programs must be based on current, high-quality evidence. Previous studies have identified seven effective preventive interventions: case management, detection and therapeutic approach to depression, improvement of record systems, identification of local determinants, awareness campaigns, training of key agents or gatekeepers, and promotion of specific research.

Regarding the modality of interventions, evidence suggests that brief (six-twelve weeks) and ultra-brief (one-four weeks) programs are particularly promising due to their versatility and implementation in diverse clinical settings. Likewise, the importance of self-awareness in mental health has been highlighted in contrast to usual and conventional non-specific treatments, identifying key psychological factors for mitigating suicide risk. A key example in this field is the Zero Suicide model, based on the premise that "every suicide is potentially preventable." The application of this model in outpatient mental health settings by multidisciplinary teams has yielded statistically significant results. This model used the Columbia Suicide Severity Rating Scale (C-SSRS) as its primary assessment tool.

However, the implementation of intensive community programs still faces critical challenges. There remains a need for further research to determine the acceptability, treatment adherence, and clinical efficacy of these interventions in the community setting.

OBJECTIVES

1. Primary Objective:

   • To evaluate the impact of a Suicide Prevention Program (SPP) on the incidence of suicidal behavior in adults at moderate-to-high risk, compared to usual care (UC), at three and twelve months of follow-up, at the Salamanca University Hospital Complex (CAUSA). Incidence will be measured by the occurrence of new episodes of suicidal ideation, suicide attempts, or completed suicide, assessed using the Columbia Suicide Severity Rating Scale (C-SSRS).

2. Secondary Objectives:

   • To compare the number of emergency department visits for suicidal behavior between both groups during the follow-up period. (Hospital records)
   • To assess the reduction in emergency hospital admissions for suicidal behavior during the SPP and at twelve months of follow-up. (Hospital records)
   • To identify the clinical, sociodemographic, and psychosocial factors associated with suicidal behavior in the study population. • Monitor the evolution of suicide risk throughout the program and during follow-up, assessed using the Columbia Suicide Severity Rating Scale (C-SSRS) at three and twelve months of follow-up.
   • Evaluate program adherence and participant satisfaction (ad hoc scale).

HYPOTHESIS

The implementation of a specific, multidisciplinary, and high-resolution program focused on the prevention and management of suicidal behavior will result in a significantly greater reduction in the incidence of new episodes of suicidal behavior (suicidal ideation, suicide attempt, and completed suicide). This will be compared with those receiving usual care (TC) at two time points: three and twelve months of follow-up. The aim is to improve mental health indicators and increase adherence to therapeutic interventions in adults at moderate-to-high risk in the Salamanca health area.

METHODS AND ANALYSIS

1. Design.

   A quasi-experimental, ambispective cohort study with two parallel groups was conducted: a control group (retrospective cohort) receiving usual treatment (HT) with data obtained from a review of medical records at the CAUSA (University Hospital of Salamanca), and an intervention group (prospective cohort) receiving the Suicide Prevention Program (PPS) with pre-intervention (baseline), post-intervention (3 months), and 12-month follow-up assessments. Group assignment was performed without randomization, in accordance with the TREND (Transparent Reporting of Evaluations with Non-Randomized Designs) declaration (13) and based on compliance with the previously established inclusion criteria.

   The study setting was the University Hospital of Salamanca (psychiatric emergency department as the referral source) and two outpatient mental health centers within the Salamanca Specialized Care Management.

2. Study Population.

   Study participants will be recruited from the CAUSA Emergency Department after an initial assessment and stabilization by psychiatry. Those subjects who meet the selection criteria specified below will be included in the intervention group (PPS). Conversely, patients with prior follow-up by the mental health team will form part of the control group (TH).

3. Sample Size.

   The sample size was calculated based on the study by Goñi-Sarriés et al. (2022), which reported a recurrence rate of suicidal behavior of 31.4% at one year of follow-up in a population hospitalized for suicide attempts in Spain. Assuming a clinically relevant 50% reduction in the proportion of new episodes in the PPS group (from 31% to 15%), with 90% statistical power and a two-tailed significance level of 0.05, the minimum required sample size was 82 participants per group (Fleiss formula for comparing proportions). Estimating a 10% dropout rate, the adjusted sample size was 91 participants per group. Given the quasi-experimental design without randomization, a propensity score matching analysis will be performed to control for potential selection bias.

4. Recruitment and procedures.

   Patients seen in the CAUSA Emergency Department who do not meet the inclusion criteria will be assigned to the control group and will receive standard treatment (ST) for suicide risk.

   Patients who do meet the inclusion criteria will be referred from the CAUSA Emergency Department to the PPS to participate in the intervention group. A researcher, a mental health nurse specialist, will make initial telephone contact with each participant within 24 hours of referral to schedule the first in-person visit at the mental health center. During this initial visit, the first link in the therapeutic relationship will be established by welcoming the patient and their family and conducting a biopsychosocial assessment to identify the primary precipitating factor and associated risk and protective factors. A basic safety plan will then be developed. The study will be presented, any questions the participant may have will be answered, and the informed consent form and the program's therapeutic contract will be signed.

   Data will be collected using a standardized data collection form, coded according to the previously defined primary and secondary variables. The recruitment period will last 12 months. For data processing, two separate databases will be maintained: one containing identifying information hosted on the SACYL network, and another anonymized database for statistical analysis, in accordance with current data protection regulations. The data will be anonymized using a numerical code that does not allow for direct identification of the participant.

   Evaluations will be conducted at three points in time: at the initial visit (baseline), at the end of the program (at 3 months), and 12 months after the first contact.

5. Definition of the Intervention.

   The Suicide Prevention Program (PPS) is a high-resolution, outpatient program carried out by a multidisciplinary team consisting of two mental health nurses, two psychiatrists, two psychologists, and two social workers. It is implemented in two community mental health centers in Salamanca, belonging to the Specialized Care Management, over a period of three months. It is applied to all patients referred from the psychiatric emergency department of the Salamanca University Hospital Complex who meet the inclusion criteria.

   Referral to the program will be made via corporate email, accessible only to team members. The referral must include a suicide risk assessment based on the patient's history, psychopathological examination, and the application of the C-SSRS by the emergency psychiatry team. The patient will be evaluated and stabilized, both physically and behaviorally, prior to referral.

   Initial Telephone Contact (< 24 hours) The first contact with the patient will be made by telephone within 24 hours of referral and will be conducted by a mental health nurse. During this contact, the nurse will ensure that the patient and their family comply with the initial recommendations and safety measures provided in the emergency department until the first in-person appointment.

   First Nursing Consultation (< 72 hours) The first in-person contact will take place in a nursing consultation within 72 hours of referral. During this consultation, the patient and their family will be welcomed, the therapeutic relationship will be established, and a comprehensive biopsychosocial assessment will be conducted using Marjory Gordon's functional health patterns. Information will be provided about the development of the Personal Safety Plan (PSP), and informed consent and the therapeutic contract will be signed. The nurse will guide the patient in developing the Safety Plan (Stanley & Brown, 2012) (25), a brief and collaborative intervention tool designed to mitigate the acute risk of suicide. As a complementary resource, the Reasons for Living Inventory (Linehan et al., 1983), composed of 48 items with Likert-type responses (1-6), will be used. The study's assessment instruments (HADS, BIS-11, CGI-SS) will also be administered.

   First psychiatric consultation (< 72 hours) Within a maximum of 72 hours from referral, the patient will have their first consultation with the team's psychiatrist, who will conduct the clinical and psychopathological evaluation, diagnosis, and psychopharmacological management.

   First psychology consultation (≤ 7 days) Within a maximum of 7 days, the patient will have their first consultation with the team's psychologist, who will be responsible for the psychological and psychometric evaluation and the design of individual psychotherapeutic interventions. First social work consultation (≤ 14 days) Within a maximum of 14 days, the patient will have their first consultation with the team's social worker, who will conduct a social assessment of the patient and their environment, and provide information on available benefits and resources, coordinating with social services when necessary.

   Follow-up consultations In-person and/or telephone follow-up consultations will be scheduled based on the patient's clinical situation and progress, agreed upon between each professional and the participant. Suicide risk will be assessed at each follow-up consultation using the CGI-SS scale.

   After assessment by all team members, an Individualized Care Plan (ICP) will be developed and reviewed weekly at the PPS team meetings.

   Group therapy Group therapy will begin once all team members have assessed the patient and the ICP has been developed. It will consist of 10 weekly sessions, each lasting one hour, with a maximum of 10 patients per session. The contents are detailed in Table 1. Content of the group sessions of the Suicide Prevention Program (PPS).

   SESSION CONTENT

   Section 1: Introduction. Understanding suicide. Section 2: Self-esteem and personal identity. Section 3: Problem-solving techniques. Section 4: Emotional identification and management. Section 5: Communication techniques and skills. Section 6: Negative thoughts and cognitive distortions. Section 7: Crisis management. Safety plan. Section 8: Keys to reducing stress. Section 9: Relaxation techniques. Section 10: Closing and farewell.

   Program completion.

   At the end of the PPS (3 months), the severity of suicide risk will be reassessed using the C-SSRS. The team will decide on the most appropriate continuation of care: discharge with follow-up by primary care, referral to the usual community mental health team, or another service within the mental health network.

6. Statistical analysis.

The variables will be collected in a database using SPSS version 28. An intention-to-treat (ITT) analysis will be performed, so the results of all individuals will be analyzed regardless of whether they complete the PPS or not. The normality of the variables will be assessed using the Kolmogorov-Smirnov test. Sample characteristics will be expressed using frequency distributions and percentages for categorical variables, and using means and standard deviations for quantitative variables. In the case of parametric distributions, the association between variables will be analyzed using the Student's t-test and analysis of variance (ANOVA). If the data do not follow a normal distribution, the corresponding non-parametric tests will be used. For the comparison of means between two time points within the same group, the paired Student's t-test (or the Wilcoxon signed-rank test for non-parametric samples) will be used. The relationship between quantitative variables will be analyzed using the Pearson or Spearman correlation coefficient, as appropriate. A repeated measures analysis (3-time ANOVA at baseline, 3 months, and 12 months) will be performed to evaluate the evolution of the variables over time. The level of statistical significance will be set at p < 0.05 for all two-tailed tests.

ETHICAL CONSIDERATIONS.

This study has been approved by the Research Ethics Committee for Medicinal Products (CEIm) of the Salamanca University Hospital Complex (CEIm code: PI 2025 11 2102 - TD) and will be conducted in accordance with the principles of the World Medical Association's Declaration of Helsinki, the International Council for Clinical Practice (ICH) Good Clinical Practice Guidelines (GCP), and Spanish Law 14/2007, of July 3, on Biomedical Research. The confidentiality of participants' data will be guaranteed at all times, in accordance with Regulation (EU) 2016/679, the General Data Protection Regulation (GDPR), and Spanish Organic Law 3/2018, of December 5, on the Protection of Personal Data and Guarantee of Digital Rights (LOPDGDD).

- Informed Consent.

All participants will be asked to sign informed consent prior to their inclusion in the study, in compliance with the requirements of the Ethics Committee and the Declaration of Helsinki. Participants will be informed of the study objectives and the associated risks and benefits.

DISCUSSION.

Clinical and Health Relevance.

This work addresses one of the WHO's priority objectives: reducing the suicide mortality rate by one-third by 2030, in line with the United Nations Sustainable Development Goals (SDGs). The described PPS could be replicated in other health areas, constituting a strategic contribution in the context of the global increase in suicide rates. From a healthcare perspective, the PPS has the potential to reduce emergency room visits and hospital admissions, freeing up resources and decreasing costs, while prioritizing care for individuals within their community and promoting earlier prevention.

Scientific and Academic Relevance.

The research group aims to publish the results in high-impact scientific journals at the national and international levels. This protocol forms part of a doctoral thesis compiled from a collection of articles. Furthermore, the study seeks to contribute to raising social awareness about suicide preventability by disseminating results through social media and other media outlets.

Limitations.

The study has the following limitations: 1. The retrospective control group does not allow for randomization or control of all possible confounding factors, thus limiting the causal attribution of the observed changes exclusively to the PPS (Personalized Prevention Program); 2. The nature of the intervention makes blinding participants unfeasible; however, the evaluators and data analyst will be blinded to participant allocation; 3. The expected loss-to-follow-up rate (30%) may affect the statistical power; 4. Recruitment at a single hospital center may limit the generalizability of the results.

Enviar comentarios

• Study Type: Interventional
• Enrollment (Estimated): 198
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Lourdes Ollero Malagón, Mental health nurse specialist; Phone Number: +34682539709; Email: lollero@saludcastillayleon.es

Study Locations

• Spain
  • Salamanca
    • Salamanca, Salamanca, Spain, 37185
      • Recruiting
      • Hospital Universitario de Salamanca

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients ≥ 18 years of age.
• No prior active follow-up by the mental health team.
• Prior stabilization by the emergency psychiatry team.
• Columbia Severity Rating Scale (C-SSRS) score corresponding to moderate-to-high risk.
• Absence of criteria for urgent hospital admission.
• Signed informed consent.

Exclusión Criteria:

• Self-harm without suicidal intent.
• Mild suicide risk (mild C-SSRS).
• Extremely high suicide risk requiring urgent hospital admission.
• Patient under active follow-up at another mental health unit.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intervention group (PPS); Intervention group with application of the high-resolution program for the prevention of suicidal behavior in adults at risk.	Behavioral: PPS; SUICIDE PREVENTION PROGRAM; The Suicide Prevention Program (PPS) is a high-resolution, outpatient program delivered by a multidisciplinary team consisting of two mental health nurses, two psychiatrists, two psychologists, and two social workers. It operates in two community mental health centers in Salamanca, belonging to the Specialized Care Management, over a three-month period. The first contact with the patient will be made by telephone within 24 hours of referral by a mental health nurse. The first in-person appointment will take place in a nursing consultation within 72 hours. The patient will have a maximum of 72 psychiatric appointments, a maximum of seven days for the first appointment with a psychologist, and a maximum of 14 days for the first appointment with a social worker. The program also includes 10 group sessions, in-person and telephone follow-up, and crisis intervention.
No Intervention: Control group (TH); Control group with application of usual treatment in patients with suicidal behaviors

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Recurrence of Clinically Significant Suicidal Behavior	Proportion of participants experiencing at least one clinically significant suicidal event during follow-up, defined as: (1) a new suicide attempt documented in the emergency department or clinical records; (2) urgent psychiatric hospitalization in a Short-Stay Inpatient Unit (UHB) due to suicidal behavior; or (3) completed suicide. Assessment Tool: Prospective registry via electronic clinical records (SACYL). For suicide attempts: emergency department records. For hospitalizations: inpatient admission records. For completed suicide: civil registry and/or clinical team notification. Scale: Dichotomous outcome (presence/absence of recurrence) and discrete quantitative variable (number of events: 0, 1, 2, 3...).	3 months (end of program) and 12 months from first contact.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Type of Suicidal Behavior	Measure: Method or type of suicidal behavior at index episode. Assessment Tool: Clinical records (emergency department psychiatric assessment). Scale: Categorical: 1. Suicidal ideation · 2. Drug overdose · 3. Chemical intoxication · 4. Gas inhalation · 5. Venipuncture · 6. Defenestration · 7. Firearm · 8. Sharp object · 9. Self-induced asphyxia.	Baseline.
Suicidal Ideation Severity.	Measure: Severity of suicidal ideation at baseline, end of program, and 12-month follow-up. Assessment Tool: Columbia Suicide Severity Rating Scale (C-SSRS) - Spanish validated version (Giner et al., 2014). Clinician-administered scale with 6 items assessing the type and intensity of suicidal ideation and suicidal behavior. High sensitivity and specificity for suicidal risk stratification. Scale: 0 = No risk · 1 = Low (C-SSRS 1-2) · 2 = Moderate (C-SSRS 3-5) · 3 = High (C-SSRS ≥6).	Baseline, 3 months, 12 months.
Emergency Department Visits due to Suicidal Ideation	Measure: Number of emergency department episodes motivated exclusively by new suicidal ideation (without suicide attempt) during follow-up. Assessment Tool: Electronic clinical records (SACYL). Scale: Discrete quantitative variable (number of episodes: 0, 1, 2, 3...).	3 months, 12 months.
Global Clinical Impression of Suicidal Risk - Severity (CGI-SS-S)	Measure: Clinician-rated global severity of suicidal risk at baseline, end of program, and 12-month follow-up. Assessment Tool: Clinical Global Impression - Suicide Scale (CGI-SS). Clinician-administered 7-point scale specifically designed for the global clinical evaluation of suicidal risk. Assesses severity at a given time point (CGI-SS-S) and improvement or worsening relative to the previous assessment (CGI-SS-I). Widely used in clinical trials on suicidal behavior. Scale: 0 = Not assessed · 1 = Normal · 2 = Borderline ill · 3 = Mildly ill · 4 = Moderately ill · 5 = Markedly ill · 6 = Severely ill · 7 = Extremely ill.	Baseline, 3 months, 12 months.
Global Clinical Impression of Suicidal Risk - Improvement (CGI-SS-I)	Measure: Clinician-rated global improvement of suicidal risk at end of program and 12-month follow-up relative to baseline. Assessment Tool: CGI-SS (see above). Scale: 0 = Not assessed · 1 = Very much improved · 2 = Much improved · 3 = Minimally improved · 4 = No change · 5 = Minimally worse · 6 = Much worse · 7 = Very much worse.	3 months, 12 months.
Anxiety and Depressive Symptomatology	Measure: Anxiety and depressive symptom severity at baseline. Assessment Tool: Hospital Anxiety and Depression Scale (HADS) - Spanish validated version (Tejero et al., 1986). Self-administered 14-item scale (7 anxiety, 7 depression), Likert response (0-3). Designed for medical and non-psychotic psychiatric patients. Cut-off ≥8 for probable case. Scale: 0 = Normal (HADS 0-7) · 1 = Borderline case (HADS 8-10) · 2 = Probable case (HADS ≥11).	Baseline.
Impulsivity	Measure: Level of impulsivity as a risk factor for suicidal behavior. Assessment Tool: Barratt Impulsiveness Scale-11 (BIS-11) - Spanish validated version (Oquendo et al., 2001). 30-item Likert scale (1-4) measuring three impulsivity dimensions: attentional, motor, and non-planning. Clinician-administered. Scale: 1 = Low (BIS 30-52) · 2 = Medium (BIS 53-71) · 3 = High (BIS ≥72).	Baseline.
Patient Satisfaction with the Program	Measure: Participant's subjective experience with the PPS across eight dimensions: overall satisfaction, expectation fulfillment, content adequacy, professional care quality, communication, organization, resources, and personal impact. Assessment Tool: Ad hoc self-administered satisfaction questionnaire (study-specific). 8-item Likert scale (0-4). Scale: 0 = Not at all satisfied → 4 = Very satisfied (overall item); domain-specific response options per item.	End of program (3 months).
Adherence to the PPS Program	Measure: Percentage of scheduled sessions attended by the participant. Assessment Tool: Attendance registry (clinical records). Scale: 0 = Did not attend · 1 = High adherence (≥80%) · 2 = Moderate adherence (50-79%) · 3 = Low adherence (≤50%).	3 months (end of program).
Sociodemographic Characteristics	Measure: Age, gender, country of origin, health area, marital status, employment status, living situation, educational level, month of referral. Assessment Tool: Clinical records. Scale: Mixed: continuous (age), categorical (gender, marital status, employment, education, cohabitation).	Baseline.
Clinical Risk Factors for Suicidal Behavior	Measure: Prior suicidal ideation, previous suicide attempts, family history of suicide, grief, recent retirement, childhood and adult abuse/maltreatment, screen time, social media use, online suicide-related search behavior, non-suicidal self-injury, verbal warning signs, social withdrawal, preparatory behaviors, sleep disturbance. Assessment Tool: Clinical records, structured clinical interview. Dichotomous (yes/no) or ordinal per variable (see study protocol).	Baseline.
Substance Use	Measure: Use of tobacco, alcohol, caffeine, cannabis, stimulants, opioids, hallucinogens, non-prescribed sedatives/hypnotics/anxiolytics; ex-user status. Assessment Tool: Structured clinical interview. Alcohol quantified via Standard Drink Unit (SDU: 1 SDU = 10 g pure alcohol). Scale: Ordinal per substance (frequency/quantity categories; see study protocol).	Baseline.
Psychiatric Diagnosis	Measure: Primary and secondary psychiatric diagnoses; prior mental health treatment and adherence. Assessment Tool: Structured clinical interview; ICD-11 / DSM-5 criteria. Scale: Categorical: anxiety disorder, mood disorder, psychotic disorder, eating disorder, personality disorder, neurodevelopmental disorder, PTSD, other.	Baseline.
Protective Factors	Measure: Active leisure activities, financial stability, safe housing, presence of vital goals, perceived socio-family support, pet ownership. Assessment Tool: Structured clinical interview; perceived social support scale. Scale: Dichotomous (yes/no) or ordinal (perceived support: none / family / social / socio-family).	Baseline.
Precipitating Factors	Measure: Recent acute stressors acting as immediate triggers for the suicidal crisis: family, social, occupational, cultural, or romantic conflict; romantic breakup; ongoing legal proceedings. Assessment Tool: Structured clinical interview; clinical records. Scale: Dichotomous (yes/no) per item.	Baseline.
Physical pain (Visual Analog Scale, VAS)	Measure: Self-reported physical pain intensity on a one-dimensional scale of 0 to 10 cm (0 = no pain; 10 = maximum imaginable pain). A higher score indicates greater pain intensity. Assessment tool: Visual Analogue Scale (VAS): self-administered one-dimensional scale, 0-10 cm. Scale: Continuous (cm, 0-10).	Baseline.

Collaborators and Investigators

• Sponsor: University of Salamanca
• Collaborators: Sanidad de Castilla y León

Publications and helpful links

General Publications

• Stanley B, Brown GK, Brenner LA, Galfalvy HC, Currier GW, Knox KL, Chaudhury SR, Bush AL, Green KL. Comparison of the Safety Planning Intervention With Follow-up vs Usual Care of Suicidal Patients Treated in the Emergency Department. JAMA Psychiatry. 2018 Sep 1;75(9):894-900. doi: 10.1001/jamapsychiatry.2018.1776.
• Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011 Dec;168(12):1266-77. doi: 10.1176/appi.ajp.2011.10111704.
• Bostwick JM, Pabbati C, Geske JR, McKean AJ. Suicide Attempt as a Risk Factor for Completed Suicide: Even More Lethal Than We Knew. Am J Psychiatry. 2016 Nov 1;173(11):1094-1100. doi: 10.1176/appi.ajp.2016.15070854. Epub 2016 Aug 13.
• Zalsman G, Hawton K, Wasserman D, van Heeringen K, Arensman E, Sarchiapone M, Carli V, Hoschl C, Barzilay R, Balazs J, Purebl G, Kahn JP, Saiz PA, Lipsicas CB, Bobes J, Cozman D, Hegerl U, Zohar J. Suicide prevention strategies revisited: 10-year systematic review. Lancet Psychiatry. 2016 Jul;3(7):646-59. doi: 10.1016/S2215-0366(16)30030-X. Epub 2016 Jun 8.
• Des Jarlais DC, Lyles C, Crepaz N; TREND Group. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health. 2004 Mar;94(3):361-6. doi: 10.2105/ajph.94.3.361.
• Herrero MJ, Blanch J, Peri JM, De Pablo J, Pintor L, Bulbena A. A validation study of the hospital anxiety and depression scale (HADS) in a Spanish population. Gen Hosp Psychiatry. 2003 Jul-Aug;25(4):277-83. doi: 10.1016/s0163-8343(03)00043-4.
• Linehan MM, Goodstein JL, Nielsen SL, Chiles JA. Reasons for staying alive when you are thinking of killing yourself: the reasons for living inventory. J Consult Clin Psychol. 1983 Apr;51(2):276-86. doi: 10.1037//0022-006x.51.2.276. No abstract available.
• Maskey-Warzechowska M, Przybylowski T, Hildebrand K, Wrotek K, Wiwala J, Kosciuch J, Chazan R. [Maximal respiratory pressures and exercise tolerance in patients with COPD]. Pneumonol Alergol Pol. 2006;74(1):72-6. Polish.
• Kondziella D, Hammer J, Sletvold O, Sonnewald U. The pentylenetetrazole-kindling model of epilepsy in SAMP8 mice: glial-neuronal metabolic interactions. Neurochem Int. 2003 Dec;43(7):629-37. doi: 10.1016/s0197-0186(03)00093-7.
• O'Neill LP, Turner BM. Immunoprecipitation of native chromatin: NChIP. Methods. 2003 Sep;31(1):76-82. doi: 10.1016/s1046-2023(03)00090-2.
• Goni-Sarries A, Yarnoz-Goni N, Lopez-Goni JJ. Psychiatric Hospitalization for Attempted Suicide and Reattempt at the One-Year Follow-Up. Psicothema. 2022 Aug;34(3):375-382. doi: 10.7334/psicothema2021.455.
• Stanley B, Brodsky B, Monahan M. Brief and Ultra-Brief Suicide-Specific Interventions. Focus (Am Psychiatr Publ). 2023 Apr;21(2):129-136. doi: 10.1176/appi.focus.20220083. Epub 2023 Apr 14.
• Fakhari A, Azizi H, Farahbakhsh M, Esmaeili ED. Effective Programs on Suicide Prevention: Combination of Review of Systematic Reviews with Expert Opinions. Int J Prev Med. 2022 Mar 12;13:39. doi: 10.4103/ijpvm.IJPVM_454_20. eCollection 2022.
• Pompili M, De Berardis D, Dell'osso B, Forte A, Innamorati M, Rogante E, Sarli G, Serafini G, Amore M. Suicide and suicidal behaviors: insight into clinical challenges and preventive measures. Expert Rev Neurother. 2025 Sep;25(9):1011-1026. doi: 10.1080/14737175.2025.2542764. Epub 2025 Aug 17.

Study record dates

Study Major Dates

• Study Start (Actual): May 1, 2025
• Primary Completion (Actual): May 1, 2026
• Study Completion (Estimated): May 1, 2027

Study Registration Dates

• First Submitted: May 15, 2026
• First Submitted That Met QC Criteria: June 15, 2026
• First Posted (Actual): June 18, 2026

Study Record Updates

• Last Update Posted (Actual): June 18, 2026
• Last Update Submitted That Met QC Criteria: June 15, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Keywords: Cohort study; Suicide prevention; Suicidal behavior; Suicidal ideation; Community mental health services; Patient care team; Quasi-experimental study; Psychiatric emergency services
• Additional Relevant MeSH Terms: Behavioral Symptoms; Self-Injurious Behavior; Suicide; Behavior; Suicide Prevention; Suicidal Ideation; Sulfur Compounds; Organic Chemicals; Carbohydrates; Sulfur Acids; Polysaccharides; Sulfuric Acids; Pentosan Sulfuric Polyester
• Other Study ID Numbers: PI 2025 11 2102 - TD (Registry Identifier: CEIM)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Individual participant data (IPD) will not be publicly shared to protect patient confidentiality. Only aggregated and anonymized results will be disseminated through scientific publications or presentations.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No